38987-01-8

Upstream product

• 117705-59-6 5-allyl-4-hydroxy-2-methoxyacetophenone 
• 117705-60-9 1-(4-allyloxy-2-methoxy-phenyl)-ethanone 
• 40815-74-5 4-allyloxy-2-hydroxyacetophenone 
• 89-84-9 2',4'-dihydroxy-4-acetophenone 

Downstream Products

• 117690-49-0 4-Pentyloxy-2-hydroxy-5-allylacetophenone 
• 117690-47-8 4-(Hexyloxy)-2-hydroxy-5-allylacetophenone 
• 117705-92-7 4-(4-cyanobutoxy)-5-allyl-2-hydroxyacetophenone 
• 117690-60-5 6-(4-Acetyl-5-hydroxy-2-allylphenoxy)-hexanenitrile 
• 117690-52-5 4-(4-Hydroxybutoxy)-5-allyl-2-hydroxyacetophenone 
• 117706-50-0 4-(5-Hexynyloxy)-2-hydroxy-5-allylacetophenone 
• 117706-53-3 [3-(4-Acetyl-2-allyl-5-hydroxy-phenoxymethyl)-phenyl]-acetonitrile 
• 117690-62-7 9-(4-Acetyl-5-hydroxy-2-allylphenoxy)-nonanenitrile 
• 117706-39-5 4-(10-Bromodecyloxy)-5-allyl-2-hydroxyacetophenone 
• 117690-56-9 4-[(4-Acetyl-5-hydroxy-2-allylphenoxy)methyl]benzonitrile 
• 117690-65-0 4-(4-Acetyl-5-hydroxy-2-allylphenoxy)-butanenitrile 
• 117705-99-4 6-(4-acetyl-2-allyl-5-hydroxyphenoxy)hexanehydroxamic acid 
• 117706-22-6 6-(4-acetyl-2-allyl-5-hydroxyphenoxy)-N,N-dimethylhexanamide 
• 117706-19-1 6-(4-acetyl-2-allyl-5-hydroxyphenoxy)hexanoic acid methyl ester 

Relevant academic research and scientific papers

Regioselectivity in aromatic Claisen rearrangements

Theoretical calculations and the isomeric product composition for a series of eight meta-substituted allyl aryl ethers confirm the reliability of a new 1H NMR methodology used to predict aromatic Claisen regioselectivity from ground-state confo

Leukotriene B4 Receptor Antagonists: The LY255283 Series of Hydroxyacetophenones

A series of hydroxyacetophenones was prepared for evaluation as leukotriene B4 (LTB4) receptor antagonists, culminating in 1-oxy>phenyl>ethanone (compound 35, LY255283).Using an assay for inhibition of specific LTB4 binding to human PMN, we found that substitution of a nonpolar substituent in the 5-position was required for activity.Best activity was realized with hydrogen in the 3-position, hydroxyl in the 2-position, short chain alkyl ketone in the 1-position, and a six- or eight-carbon chain linking the oxygen in the 4-position with an unsaturated terminal function.Compound 35, having an IC50 of 87 nM in the binding assay, was chosen for further preclinical evaluation.

ANTI-INFLAMMATORY AGENTS

This invention provides benzene derivatives, pharmaceutical formulations of those derivatives, and a method of using the derivatives for the treatment of inflammation in mammals.